Abstract Body

Background: HIV-associated neurocognitive disorders (HAND) remain prevalent and recent work by Grant and colleagues (2014) demonstrated that asymptomatic neurocognitive impairment (ANI) is associated with a 2-5 risk for the development of symptomatic HAND (mild neurocognitive impairment [MND] or HIV-associated dementia [HAD]) in persons followed in CHARTER. We were interested in replicating and extending these results in a Canadian sample.

Methods: Study sample included 575 adults who are enrolled in the Ontario HIV Treatment Network Cohort Study (OCS) and who were either neuropsychologically normal (NP-Normal; n=299) or had ANI (n=276) at baseline. Neuropsychological testing was done every 12 months (median follow-up time: 30 months) using a brief test battery that included Hopkins Verbal Learning Test- Revised (HVLT-R), Grooved Pegboard, and WAIS-R Digit Symbol. Cognitive complaints were assessed with four-item Medical Outcomes Study Cognitive Functioning scale. HAND status was assigned according Antinori et al., (2007) criteria. We used proportional hazards regression modelling to generate risk ratios for progression to MND or HAD after adjusting for baseline and time-varying covariates.

Results: Participants: 82% men, 64% Caucasian, 86% on cART, and 73% had undetectable HIV viral load at baseline. Over the follow-up period, 99 individuals (39 who were NP-N and 60 who had ANI at baseline) showed progression to MND or HAD. Participants with ANI had shorter time of progression to MND or HAD than those who were NP-Normal at baseline after adjusting for baseline and time-varying predictors: adjusted hazards ratio 1.85 (95% confidence interval: 1.12-2.82; p=0.005). Among the covariates examined, depression and current smoking were significant predictors of higher risk of progression, while undetectable plasma HIV viral load was significantly associated with lower risk of progression to MND or HAD . Low nadir CD4 (<200 cells/mm3) was not a significant predictor of progression in adjusted analyses although it was associated with higher risk prior to adjustment for covariates.

Conclusions: Asymptomatic Neurocognitive Impairment is associated with almost two-fold increased risk of progression to symptomatic HAND. Early treatment with cART and addressing medical and mental comorbidities may delay or lower risk of the development and progression of symptomatic HAND.